SS Innovations International Inc. Common Stock
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems. The company also develops NADI " Automated Coronary Anastomotic Connector, a micro stapling device; SSi Multi-Fire Clip Applier, a cartridge-based clip applicator; SSi Robotic Stapler; SSi Maya " XR Pre-Operative Simulator, a robotic surgery platform; SSi Holographic Anatomy, an augmented reality tool; SSi Chitrasa " Advanced DICOM Viewer, an AI enabled application viewer; and SSi Mixed Reality Headset, a medical-grade device. In addition, it offers instrument tips, including forceps, scissors, electrocautery tools, scalpels, and other surgical tools. Further, the company provides accessory products, such as sterile drapes, 3d stereo endoscopes, cannulas, and seals, as well as tele proctoring and telesurgery products. Additionally, it offers installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring services. The company sells its products through direct sales organizations and distributor networks. SS Innovations International, Inc. is headquartered in Gurugram, India.
Open SSII dashboard ↗United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Open UTHR dashboard ↗